Pharvaris NV (Pharvaris NV) Debt-to-Revenue : N/A (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharvaris NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.13 Mil. Pharvaris NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.08 Mil. Pharvaris NV's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Pharvaris NV Debt-to-Revenue Historical Data

The historical data trend for Pharvaris NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Debt-to-Revenue Chart

Pharvaris NV Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

Pharvaris NV Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Pharvaris NV's Debt-to-Revenue

For the Biotechnology subindustry, Pharvaris NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharvaris NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's Debt-to-Revenue falls into.

Pharvaris NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharvaris NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.213	+	0.048)	/	N/A
	=	N/A

Pharvaris NV's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.13	+	0.076)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Pharvaris NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharvaris NV (Pharvaris NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

9EN:Germany

Address

Emmy Noetherweg 2, Leiden, NLD, 2333 BK

Website

https://www.pharvaris.com

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.